Roundtable Discussion: Discussing the Role of Innate Immunity in Clinical Manifestations of Immunogenicity

Time: 3:00 pm
day: Day 1 Tracks 2 PM


Immunogenicity of AAV is complex and challenging, involving elements of innate, humoral and cellular immunity that can adversely impact patient eligibility, safety, efficacy, durability of treatment, and ability to re-dose. Innate immunity in widely accepted to be the first in a chain of immune responses but there is still much to be understood. This roundtable will set out to discuss: – – – current understandings of Innate immune responses to the Capsid & Transgene & its impact on long term & short-term efficacy & safety?